Patents by Inventor Saiyi ZHONG

Saiyi ZHONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240247293
    Abstract: This present disclosure provides a method for preparing chondroitin sulfate from tilapia skull, including enzymatic hydrolyzing tilapia skull powder by Savinase 16L to obtain Savinase 16L enzymatic hydrolysate, re-enzymatic hydrolyzing the Savinase 16L enzymatic hydrolysate by 2709 alkaline protease, then separating and purificating the solution by ethanol and cetylpyridine chloride to obtain the chondroitin sulfate. The present disclosure adopts a compound enzymatic hydrolyzing method by Savinase 16L and 2709 alkaline protease to effectively achieve the efficient extraction of chondroitin sulfate of tilapia skull powder, and further achieve the purification of chondroitin sulfate by ethanol and cetylpyridine chloride, so that tilapia by-products can be utilized with high value.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 25, 2024
    Inventors: Saiyi ZHONG, Gege ZUO, Jing CHEN, Jianping CHEN, Rui LI, Bingbing SONG, Kangjian CHEN, Xiaofei LIU, Xuejing JIA
  • Publication number: 20240218317
    Abstract: An application of Bacillus velezensis HL-5 capable of improving an extraction rate of heparin in aquatic products, the Bacillus velezensis HL-5 is preserved in Guangdong Microbial Culture Collection Center on Jul. 2, 2018, with a preservation number of GDMCC No.: 60403, which is applied to extract heparin from shellfish. Compared with a conventional enzymolysis method, the extraction rate of the heparin is increased by 10.55%-72.07%. The Bacillus velezensis HL-5 has a stronger capability of producing lipase and protease, and has a good application prospect in the extraction of the heparin of aquatic products.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 4, 2024
    Inventors: Saiyi ZHONG, Huanming LIU, Shouchun LIU, Pengzhi HONG, Chujin DENG
  • Publication number: 20230293574
    Abstract: The present disclosure provides an application of fish swim bladder-derived heparin-like mucopolysaccharide in the preparation of angiogenesis inhibitors, belonging to the technical field of medication. In the present disclosure, the structural unit of the fish swim bladder-derived heparin-like mucopolysaccharide is ?-?GlcUA-[1?3]-GalNAc-4S. The fish swim bladder-derived heparin-like mucopolysaccharide has strong inhibition on angiogenesis. As shown from the results of examples in the present disclosure, the inhibitory rate of 400 mg/L fish swim bladder-derived heparin-like mucopolysaccharide on the growth of human umbilical vein endothelial cells can be up to 90.3%; and the inhibitory rate of 1 mg/mL fish swim bladder-derived heparin-like mucopolysaccharide on the angiogenesis of chick embryo chorioallantoic membrane is 77.15%.
    Type: Application
    Filed: November 20, 2020
    Publication date: September 21, 2023
    Inventors: Saiyi ZHONG, Siyi ZHOU, Jing CHEN, Jianping CHEN, Suhua CHEN, Rui LI, Xuejing JIA, Xiaofei LIU